StemRIM (4599) Stock Overview
A biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4599 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
StemRIM Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥282.00 |
| 52 Week High | JP¥370.00 |
| 52 Week Low | JP¥246.00 |
| Beta | 1.01 |
| 1 Month Change | 7.22% |
| 3 Month Change | 5.22% |
| 1 Year Change | -10.76% |
| 3 Year Change | -69.64% |
| 5 Year Change | -63.89% |
| Change since IPO | -70.35% |
Recent News & Updates
Shareholder Returns
| 4599 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -5.1% | -4.0% | -0.5% |
| 1Y | -10.8% | 4.8% | 29.4% |
Return vs Industry: 4599 underperformed the JP Biotechs industry which returned 4.8% over the past year.
Return vs Market: 4599 underperformed the JP Market which returned 29.4% over the past year.
Price Volatility
| 4599 volatility | |
|---|---|
| 4599 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4599's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4599's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 45 | Masatsune Okajima | stemrim.com |
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy.
StemRIM Fundamentals Summary
| 4599 fundamental statistics | |
|---|---|
| Market cap | JP¥17.93b |
| Earnings (TTM) | -JP¥1.90b |
| Revenue (TTM) | n/a |
Is 4599 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4599 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥1.90b |
| Earnings | -JP¥1.90b |
Last Reported Earnings
Oct 31, 2025
Next Earnings Date
Mar 11, 2026
| Earnings per share (EPS) | -30.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4599 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 15:00 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/10/31 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
StemRIM is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |
| Hiroyuki Matsubara | Nomura Securities Co. Ltd. |
| Kota Maeda | Nomura Securities Co. Ltd. |